Interestingly the co. that I think would benefit most, Bod Aus...

Interestingly the co. that I think would benefit most, Bod Aus (BDA) is down 4c (10%) and MMJ is flat with low trading volume.

AC8 will benefit because this highlights the difference between the now-OTC CBD preparations and AC8's THC/CBD medication grade preparations which will remain prescriber only.

AC8 will increase in value, imo, as the differentiation makes the distinction clear.